NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):: US0894821034 (+2 more)
LEI:
Country:: United States of America
Address:: 1201 ORANGE STREET, 19801 WILMINGTON
Website:: https://www.nrxpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Humacyte, Inc. Bioengineering off-the-shelf human tissues for vascular repair and regenerative medicine.	United States of America	HUMA
Human Stem Cells Institute PJSC A biotech investor developing gene therapy, regenerative medicine, and genetic services.	Russian Federation	ISKJ
HUMASIS CO., LTD. Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.	South Korea	205470
Humedix Co., Ltd. Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.	South Korea	200670
HUONS CO., LTD. Global healthcare company providing pharmaceuticals, medical devices, and wellness products.	South Korea	243070
Huons Global Co., Ltd. Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.	South Korea	084110
Hutchmed (China) Limited	Hong Kong	HCM
HUTCHMED (China) Ltd Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.	United States of America	HCM
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL